Because of the high risk of thrombosis, cancer patients often receive anticoagulants as
prophylaxis or treatment. It has been suggested that antithrombotic agents influence cancer …

The association between thrombosis and cancer is well known and the first description of
venous thrombosis as a complication of malignant disease by Trousseau dates back to …

Thromboembolic events contribute significantly to the morbidity and mortality in cancer.
Effective and safe anticoagulation-mainstay in prevention and treatment of thrombosis …

Nearly all patients with cancer manifest laboratory evidence of hypercoagulability and some
develop clinical thromboembolic disease (TED). Routine laboratory studies of blood …

The relationship between thromboembolic disorders and cancer would only stir an
occasional glance from physicians who treat cancer patients. This lack of interest probably …

Remarkable progress has been made since the first description of the association between
cancer and thrombosis by Trousseau over 100 years ago. Now, it is clear that there is a two …

The association between cancer and activation of blood coagulation has been described
since Trousseau's time. The hypercoagulable state often encountered in cancer patients not …

Rapid progress has been made recently in our understanding of the pathogenesis of
coagulation activation in malignancy and mechanisms by which the coagulation mechanism …

Coagulation disorders occur often in cancer patients. Thrombosis or embolism may be the
first sign of an underlying malignancy. In addition, subclinical coagulation disturbances have …

The blood coagulation mechanism regulates the growth and dissemination of malignancy by
multiple mechanisms, and anticoagulant drugs have been shown to inhibit the progression …